In the realm of contemporary science and healthcare, there exists an increasingly fervent excitement centered around an unassuming fungus that has captivated...
The firm says its existing cash will fund it through 2025. The post Compass Pathways Research, Clinical Trials Buoyed by Influx of New Funds appeared first...
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30,...
The company said it has enough cash to continue operations into 2026. The post MindMed Advances Medical LSD Studies for Anxiety, Autism with $177M in the...
A federal appeals court panel has begun hearing arguments in a case involving a Seattle doctor who sued the U.S. Drug Enforcement Administration for...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions....
The financials doesn't include the firm's more recent spending spree. The post Lucy Scientific Debt Climbs in Fiscal Year Report appeared first on Green...
Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously....
The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual...
5-MEO-DMT developer GH Research has provided an update on its main clinical programs. The company is notoriously short on communications outside of the...